›› 2018, Vol. 45 ›› Issue (4): 1089-1097.doi: 10.16431/j.cnki.1671-7236.2018.04.032

Previous Articles     Next Articles

Evaluation of the Therapeutic Efficacy of Antimicrobacterial Peptide NZ2114 in Mice Infected with Streptococcus suis Serotype 2

ZHAO Fei1,2,3,4, TENG Da3,4, YANG Na3,4, WANG Xiumin3,4, MAO Ruoyu3,4, HAO Ya3,4, LI Zhanzhan3,4, WANG Xiao3,4, FAN Huan2, WANG Jianhua3,4   

  1. 1. College of Life Sciences, Tianjin Normal University, Tianjin 300387, China;
    2. Tianjin Animal Science and Veterinary Research Institute, Tianjin 300381, China;
    3. Key Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing 100081, China;
    4. Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China
  • Revised:2018-02-11 Online:2018-04-20 Published:2018-04-25

Abstract:

In order to explore in vivo therapeutic efficacy of antimicrobial peptide NZ2114 against Streptococcus suis (S.suis),the evaluation was performed on the mice model,in which NZ2114 and S.suis serotype 2 CVCC 3928 were used as objects of this study.36 female ICR mice were randomly divided into 6 groups:Blank control group (no infection,intraperitoneal injection of 0.2 mL PBS),negative control group (infection,intraperitoneal injection of 0.2 mL PBS),test groups Ⅰ and Ⅱ (infection,intraperitoneal injection of 0.2 mL 2.5 and 5.0 mg/kg NZ2114,respectively),positive control groups Ⅰ and Ⅱ (infection,intraperitoneal injection of 0.2 mL 7.5 and 15.0 mg/kg ceftriaxone sodium,respectively).The results showed that the survival rates of blank control group and 5.0 mg/kg NZ2114 test group were both 100%,while that of 15.0 mg/kg ceftriaxone sodium positive control group was only 50%.The bacteria load in liver and lung decreased 59.41% (P < 0.01) and 69.19% (P < 0.01) in 5.0 mg/kg NZ2114 test group,and those of 15.0 mg/kg ceftriaxone sodium positive control group decreased 43.94% (P < 0.01) and 19.60% (P < 0.05),respectively.Compared with negative control group,the levels of TNF-α and IL-1β in mice serum decreased 85.83% (P < 0.01) and 56.20% (P < 0.05) in 2.5 mg/kg NZ2114 test group,those of 5.0 mg/kg NZ2114 test group decreased 84.02% (P < 0.01) and 43.86% (P < 0.05),and those of 15.0 mg/kg ceftriaxone sodium positive control group decreased 24.49% and 8.82%,respectively.Moreover,after treatment of 5.0 mg/kg NZ2114 for 1 d,the diffuse interstitial infiltration of inflammatory cells and other inflammatory symptoms in lung tissue obviously reduced,swelling and vacuoles changes produced by liver cells were inhibited and splenic nodules returned to normal,and the basic clinical symptoms were recovered to normal after treatment for 7 d.These results suggested that NZ2114 could effectively increase the survival rate of mice,decrease the bacterial translocation in lung and liver,inhibit the release of TNF-α and IL-1β,and relieve the lung,liver and spleen from acute injury induced by S. suis,which were better than ceftriaxone sodium and indicated that NZ2114 had a good potential as an antibiotic substitute for the treatment of S. suis serotype 2 disease.

Key words: antimicrobial peptide NZ2114; Streptococcus suis serotype 2; mice; survival rate; bacteria load in organ; inflammatory factor

CLC Number: